International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(23), С. 12929 - 12929
Опубликована: Дек. 1, 2024
Clear
cell
renal
carcinoma
(ccRCC)
is
the
most
common
kidney
malignancy,
with
a
poor
prognosis
for
advanced-stage
patients.
Identifying
key
biomarkers
involved
in
tumor
progression
crucial
improving
treatment
outcomes.
In
this
study,
we
employed
an
integrated
approach
combining
single-cell
RNA
sequencing
(scRNA-seq)
and
bulk
(bulk
RNA-seq)
to
identify
associated
ccRCC
prognosis.
Single-cell
transcriptomic
data
were
obtained
from
publicly
available
datasets,
genes
related
screened
using
Monocle2.
Bulk
RNA-seq
retrieved
The
Cancer
Genome
Atlas
(TCGA)
scRNA-seq
explore
heterogeneity.
We
identified
3
beta-hydroxy
steroid
dehydrogenase
type
7
(HSD3B7)
as
candidate
biomarker
ccRCC,
overall
survival,
disease-specific
progression-free
interval.
Elevated
HSD3B7
expression
correlated
aggressive
clinical
features
such
advanced
TNM
stages,
histologic
grades,
metastasis.
Functional
studies
demonstrated
that
promotes
proliferation,
migration,
invasion
vitro,
while
its
silencing
significantly
inhibits
growth
vivo.
Our
findings
reveal
novel
providing
insights
into
role
potential
target
therapy.
This
study
highlights
value
of
integrating
uncover
regulators
biology
lays
foundation
developing
personalized
therapeutic
strategies
Journal of Nuclear Medicine,
Год журнала:
2024,
Номер
unknown, С. jnumed.124.268509 - jnumed.124.268509
Опубликована: Ноя. 7, 2024
The
diagnosis
and
surveillance
of
clear
cell
renal
carcinoma
(ccRCC)
remains
a
clinical
challenge.
high
specific
expression
the
cluster
differentiation
70
(CD70)
in
ccRCC
makes
it
potential
diagnostic
therapeutic
target.
ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 4, 2025
Molecular
imaging
plays
a
vital
role
in
diagnosing
diseases,
monitoring
treatments,
and
evaluating
therapeutic
efficacy
by
enabling
noninvasive
visualization
of
biological
processes.
Nanobodies,
single-domain
antibodies
derived
from
camelids,
have
emerged
as
promising
candidates
for
wide
range
biomedical
applications
due
to
their
unique
properties,
including
small
size,
high
affinity,
rapid
clearance,
deep-tissue
penetration.
While
effective
radiolabeling
techniques
remain
major
challenge
fully
realize
clinical
potential,
this
review
aims
present
recent
advances
nanobody
radiolabeling,
focusing
on
radionuclides
like
64Cu,
68Ga,
89Zr,
111In,
along
with
associated
chelators
conjugation
methods.
We
highlight
the
development
innovative
chelators,
p-SCN-Bn-HOPO
desferrioxamine
derivatives
that
enhance
specificity
stability,
well
influence
biodistribution
pharmacokinetics.
These
findings
essential
nanobody-based
molecular
precise
diagnostics
targeted
therapy.
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 6, 2025
Prostate-specific
membrane
antigen
(PSMA)
is
a
potential
target
for
the
diagnosis
and
treatment
of
angiogenesis
in
clear
cell
renal
carcinoma
(ccRCC).
We
aimed
to
investigate
degree
PSMA
signal
variability
ccRCC
assess
its
correlation
with
neovascularization
tumor
microenvironment.
included
120
patients
suspected
tumors
who
underwent
[68Ga]Ga-PSMA-11
positron
emission
tomography/computed
tomography
(PET/CT)
scan
before
surgery
this
retrospective
study,
including
98
ccRCC,
17
non-ccRCC,
5
benign
diseases.
compared
maximum
standard
uptake
value
(SUVmax)
tumor-to-liver
ratio
(TLR)
primary
lesions
different
groups
analyzed
diagnostic
efficacy
imaging
ccRCC.
The
coefficient
variation
(CV)
SUVmax,
which
reflects
intertumor
heterogeneity,
volume
(VR),
intratumor
were
obtained
from
PET
imaging.
between
immunohistiochemical
(IHC)
staining,
microvessel
density
(MVD),
serum
vascular
endothelial
growth
factor
(VEGF)
inter-
heterogeneity
metastases.
In
our
showed
significantly
higher
SUVmax
TLR
non-ccRCC
diseases
(F
=
14.48,
p
<
0.001;
F
14.49,
0.001).
IHC
staining
exhibited
moderate
(r
0.421,
0.021)
MVD
0.518,
0.003),
but
it
was
not
correlated
VEGF
-0.003,
0.989).
had
0.448,
0.013)
0.345,
0.020).
Serum
weak
0.338,
0.145).
Based
on
correlation,
SUVmax-to-angiogenesis
model
validated.
mean
values
lesions,
bone
metastases,
thrombi
16.13,
18.69,
6.02,
respectively.
CV
58.5%,
55.9%,
80.6%.
VR
0.33,
0.46,
0.75,
81.8%,
41.3%,
26.7%.
corresponding
metastases
0.52,
0.011;
r
0.87,
0.024).
lesion
localized
advanced
no
significant
difference
(p
0.251),
while
0.049).
conclusion,
PET/CT
an
effective
molecular
tool
assessing
differentiating
MVD,
VEGF.
than
that
Primary
highest
high
invasive
behavior.
by
has
positive
effect
metastasis.
Sarcomatoid
differentiation
is
an
invasive
dedifferentiated
feature
of
tumor
and
associated
with
poor
prognosis
in
renal
cell
carcinoma
(RCC)
patients.
This
study
aimed
to
evaluate
the
utility
18F-FDG
PET/CT
predicting
sarcomatoid
RCC
its
potential
prognostic
value.
retrospective
assessed
newly
diagnosed
(SDRCC)
patients
who
were
staged
using
PET/CT.
Patients
categorized
into
high-grade
(HG-SDRCC),
low-grade
(LG-SDRCC),
non-sarcomatoid
(non-SDRCC).
The
maximum
standardized
uptake
value
(SUVmax),
mean
(SUVmean),
metabolic
volume
(MTV),
total
lesion
glycolysis
(TLG)
compared.
Overall
survival
(OS)
disease-free
(DFS)
analyzed.
SUVmax,
MTV,
TLG,
SUVmean
values
significantly
higher
SDRCC
compared
non-SDRCC
(P
<
0.05).
Additionally,
HG-SDRCC
non-HG-SDRCC
ROC
curves
revealed
that
SUVmax
effective
for
distinguishing
from
non-HG-SDRCC.
log-rank
test
identified
>
11,
MTV
95,
TLG
500,
5.2,
invasion
peripheral
tissue
and/or
organs,
metastasis
as
risk
factors
Multivariate
Cox
proportional
hazards
model
analyses
indicated
500
was
a
factor
DFS,
while
11
5.2
OS.
can
effectively
differentiate
more
aggressive
malignancy.
developed
this
demonstrates
parameters,
particularly
DFS
SUVmax/SUVmean
OS,
serve
robust
predictors
patient
outcomes
than
degree
differentiation.
Journal of Nuclear Medicine,
Год журнала:
2025,
Номер
unknown, С. jnumed.124.268835 - jnumed.124.268835
Опубликована: Фев. 27, 2025
CD70
is
an
emerging
biomarker
for
both
solid
tumors
and
hematologic
malignancies,
highlighting
the
urgent
need
a
molecular
imaging
tracer
capable
of
visualizing
with
favorable
pharmacokinetics.
Methods:
ABDB6
was
prepared
by
fusing
albumin-binding
domain
ABD035
CD70-targeting
single-domain
antibody
RCCB6,
which
we
previously
reported.
The
resulting
then
conjugated
to
bifunctional
chelator
p-SCN-NOTA
labeled
64Cu
produce
[64Cu]Cu-NOTA-ABDB6.
Flow
cytometry
used
screen
6
lymphoma
cell
lines
varying
expression
levels.
Cell
uptake
in
vivo
immuno-PET
studies
were
conducted
fully
evaluate
pharmacokinetic
properties
tumor-targeting
efficacy
An
blocking
study
performed
validate
targeting
specificity
[64Cu]Cu-NOTA-ABDB6,
followed
immunohistochemistry
fluorescent
immunostaining
correlate
expression.
Results:
labeling
achieved
high
radiochemical
yield
specific
activity.
Significant
observed
5
(TMD8,
HBL1,
OCI-LY10,
LCL-EBV,
type
III
latency
Burkitt
[BL]
cells)
but
not
I
BL
cells,
served
as
negative
control.
[64Cu]Cu-NOTA-ABDB6
exhibited
good
affinity
protein
at
nanomolar
level
(inhibitory
concentration
50%,
91.57
nM)
binding
human
CD70.
Immuno-PET
demonstrated
excellent
tumor
retention
various
CD70-positive
models
BL,
LCL-EBV),
highest
values
recorded
24.67
±
1.36,
18.02
4.29,
14.68
1.20
percentage
injected
dose
per
gram
tissue
(%ID/g)
48
h
after
injection,
respectively.
These
significantly
higher
than
that
CD70-negative
tumor,
had
3.59
0.28
%ID/g
same
scanning
time
point
(P
<
0.05).
In
TMD8
group,
5.99
lower
control
group
0.01).
Both
biodistribution
histology
results
corroborated
these
findings.
Conclusion:
effectively
visualized
levels
different
models.
Its
clinical
potential
may
provide
insights
into
patients.
